Categories
Blood Cancer

ZUMA-7: Axi-cel in r/r large B-cell lymphoma [Video]

Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, presents results from the Phase III ZUMA-7 trial (NCT03391466) which assessed axicabtagene ciloleucel (axi-cel), an autologous anti‑CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). 359 patients either received axi-cel or the standard of care, with the primary endpoint being event-free survival (EFS). After a 24 month follow-up, patients in the axi-cel arm demonstrated a superior EFS and overall response rate (ORR). Overall survival (OS) was additionally superior in the axi-cel arm, but was not statistically significant. The results suggest axi-cel can be a second-line treatment for r/r LBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

DLBCL updates at ASH 2021 [Video]

Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, provides key updates in the field of diffuse large B-cell lymphoma (DLBCL) that will be discussed at ASL 2021. He comments on the results from the Phase III ZUMA-7 trial (NCT03391466) which investigated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) DLBCL. Dr Cheah additionally highlights potential data from the Phase III POLARIX trial (NCT03274492), which compared polatuzumab vedotin, an antibody-drug conjugate, with R-CHP against R-CHOP. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Looking forward to ASH 2021: key updates in DLBCL [Video]

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, gives an overview of the main updates in diffuse large B-cell lymphoma (DLBCL) that will be discussed at the upcoming ASH annual meeting. To begin with, the data from the POLARIX trial comparing the efficacy of polatuzumab vedotin plus R-CHP versus R-CHOP in previously untreated DLBCL (NCT03274492) is eagerly awaited, as a recent press release reported that the primary endpoint was met. In addition, updates from the ZUMA-7 study investigating the efficacy of axicabtagene ciloleucel versus standard of care (SOC) in relapsed/refractory DLBCL (NCT03391466) will be presented at ASH, as well as new exciting data on bispecific antibodies for lymphoma. Dr Collins is also looking forward to hearing more details about the real-world data from a study evaluating the outcomes of different central nervous system (CNS) prophylaxis strategies in DLBCL which could have a substantial impact on clinical practice. Finally, an interesting study investigating the use of cell-free DNA (cfDNA) as a diagnostic and prognostic biomarker in primary CNS lymphoma will be presented at the Plenary Scientific Session. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

CAR T-cell populations associated with treatment response in lymphoma [Video]

Zinaida Good, PhD, Stanford University, Stanford, CA, discusses the results of a study investigating chimeric antigen receptor (CAR) T-cell features associated with durable response in patients with lymphoma. In this study, the number of CAR T-cells and the specific CAR-T populations present in blood were analysed at peak expansion in 32 patients receiving axicabtagene ciloleucel (axi-cel) using high-dimensional single-cell proteomics analysis. Whilst the overall number of CAR T-cells was not found to correlate with treatment response, two subsets of CAR T-cells expressing CD57 and T-bet were associated with durable remission and conversely, one CAR T-cell subset expressing regulatory T-cell (Treg) features was associated with poor response and lower incidence of neurotoxicity. These findings can be used in the clinic to determine which patients may require additional therapy, and suggest that it may be beneficial to reduce populations of regulatory cells prior to infusion in patients with increased numbers of immunosuppressive cells. These observations also support tracking CD57-expressing T-bet-positive CAR T-cells in the blood to measure clonal expansion in patients. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.